How the White House's new drug-pricing rules affect health insurers

A new Trump administration rule on drug pricing will require health insurers to publicly disclose their negotiated rates for prescription drugs, according to Kaiser Health News

The requirements were outlined in drug-pricing rules CMS released Nov. 20. They are part of the White House's broader Oct. 29 rule to require health insurers to disclose their negotiated rates for medical services with providers. 

Under the requirements outlined in the new drug-pricing rules, health insurers must give their members estimated out-of-pocket costs for prescription drugs and publish the prices they pay for drugs beginning in 2022, according to KHN. The changes don't apply to Medicare or Medicaid.

While the Trump administration said the changes will help patients make more cost-effective healthcare choices and increase competition, health insurer and pharmacy groups have denounced the changes, saying they will hurt competition and ultimately lead to higher prices. 

Read the full KHN report here.

More articles on payers:
UnitedHealth: Move routine imaging out of hospital, lower spending by 62%
5 things to know about Evernorth, Cigna's health services unit
6 recent payer-provider contract agreements, conflicts

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.